Treats chronic gouty arthritis. ANDA 84279, held by Watson Labs. Colchicine; Probenecid.
As of Nov 15, 2026, ANDA 84279 (Col-Probenecid), held by Watson Labs, was first approved by FDA on Nov 23, 1976, with 17 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE For the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 23, 1976 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Col-Probenecid0.5MG;500MG ยท tablet;oral | Colchicine; Probenecid | RxReference drug |
| May 6, 2002 | Supplement 45Manufacturing | Approved | None posted |
| Apr 25, 2001 | Supplement 44Manufacturing | Approved | None posted |
| May 31, 1991 | Supplement 41Manufacturing | Approved | None posted |
| Jan 28, 1991 | Supplement 42Manufacturing | Approved | None posted |
| Jun 29, 1990 | Supplement 39Manufacturing | Approved | None posted |
| Nov 30, 1989 | Supplement 40Labeling | Approved | None posted |
| Mar 14, 1988 | Supplement 36Manufacturing | Approved | None posted |
| Mar 14, 1988 | Supplement 37Manufacturing | Approved | None posted |
| Mar 14, 1988 | Supplement 38Manufacturing | Approved | None posted |
| Jan 22, 1985 | Supplement 32Manufacturing | Approved | None posted |
| Feb 15, 1984 | Supplement 31Manufacturing | Approved | None posted |
| Nov 9, 1983 | Supplement 30Manufacturing | Approved | None posted |
| Jun 29, 1983 | Supplement 27Manufacturing | Approved | None posted |
| Jun 29, 1983 | Supplement 28Manufacturing | Approved | None posted |
| Jun 29, 1983 | Supplement 29Manufacturing | Approved | None posted |
| Nov 30, 1982 | Supplement 26Manufacturing | Approved | None posted |
| Jan 28, 1982 | Supplement 25Manufacturing | Approved | None posted |
| Nov 23, 1976 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters